Advances in Targeting CAR-T Therapy for Immune-Mediated Diseases

In by

Spotlight Article

Expert Insight

Jinmin Lee, Aimee S Payne

Latest Advances in CAR-T Cell Manufacture & Clinical Developments

In recent years, genetically engineered cell therapies based on chimeric antigen receptor (CAR) technology have transformed the cancer treatment landscape. The groundbreaking success of CD19-specific CAR-T cell therapies in inducing lasting remissions of previously refractory B cell neoplasms has stimulated increasing interest in evaluating the potential of CAR technology to extend beyond cancer to induce safe and durable remissions of immunologic diseases. This review will highlight recent preclinical advances in targeting cytotoxic and regulatory CAR-T therapy to autoimmune and alloimmune disease indications, including pemphigus vulgaris, Factor VIII inhibitors, and HLA-mediated transplant rejection.

Submitted for peer review: Mar 27 2018 Published: May 14 2018
DOI: 10.18609/cgti.2018.026
Citation: Cell Gene Therapy Insights 2018; 4(4), 255-265.
Open access

This content is restricted to registered users. Click here to Register or Login here.